Aptamer-Functionalized Hybrid Nanostructures for Sensing, Drug Delivery, Catalysis and Mechanical Applications

Vázquez‐González, Margarita; Willner, Itamar

doi:10.3390/ijms22041803

Cited by 27 publications

(6 citation statements)

References 223 publications

(262 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42,43 Compared with antibodies, the advantages of aptamers are outstanding, such as fast in vitro screening, cell-free chemical synthesis, small size, low immunogenicity and strong tissue penetration. 44 Nucleic acid aptamers were initially created through artificial screening in 1990, and the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology, which matches enriched ligands, provided a crucial research tool for nucleic acid aptamers. SELEX enables the selection of nucleic acid aptamers with high specificity and affinity for target substances from a random single-stranded nucleic acid sequence library.…”

Section: Small Nucleic Acidmentioning

confidence: 99%

“…Aptamers are short single‐stranded oligonucleotides that fold into unique three‐dimensional structures and bind to a wide range of targets, including small molecules, proteins, metal ions, bacteria, viruses and whole cells, and its high specificity and binding affinity could reach the antibody level 42,43 . Compared with antibodies, the advantages of aptamers are outstanding, such as fast in vitro screening, cell‐free chemical synthesis, small size, low immunogenicity and strong tissue penetration 44 . Nucleic acid aptamers were initially created through artificial screening in 1990, and the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology, which matches enriched ligands, provided a crucial research tool for nucleic acid aptamers.…”

Section: Small Nucleic Acid Drug and Delivery Systemmentioning

confidence: 99%

See 1 more Smart Citation

Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect

Wang,

Tang,

Tao

et al. 2024

Interdisciplinary Medicine

View full text Add to dashboard Cite

Over the two decades, RNA drugs have gradually made their way from bench to bed. Initially, RNA was not an ideal drug since RNA molecules degrade easily and have a relatively short half‐life in the circulation system. Nevertheless, the chemical modification extended the half‐life of RNA in recent years, which makes RNA drugs a new star in drug discovery industry. RNA molecules hold many properties that facilitate their application as therapeutic drugs. RNAs could fold to form complex conformations to bind to proteins, small molecules, or other nucleic acids, and some even form catalytic centers. Protein‐encoding RNAs are the carriers of genetic information from DNA to ribosomes, and various types of non‐coding RNAs cooperate in the transcription and translation of genetic information through various mechanisms. To date, three mainstream RNA therapies have drawn widespread attention: (1) messenger RNA that encodes therapeutic proteins or vaccine antigens; (2) small interfering RNA, microRNA (miRNA), antisense oligonucleotides that inhibit the activity of pathogenic RNAs; and (3) aptamers that regulate protein activity. Here, we summarized the current research and perspectives of RNA therapies, which may provide innovative highlights for cancer therapy.

show abstract

Section: Small Nucleic Acidmentioning

confidence: 99%

Section: Small Nucleic Acid Drug and Delivery Systemmentioning

confidence: 99%

Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect

Wang,

Tang,

Tao

et al. 2024

Interdisciplinary Medicine

View full text Add to dashboard Cite

show abstract

“…These composite nanomaterials exhibit unique or enhanced functional properties due to the synergistic activity of the two components. Previous research has focused on the development of active structures that can dynamically adapt for applications such as biosensing, drug delivery, molecular logic, molecular electronics and other areas 118,119 …”

Section: Nanomaterial‐conjugated Fnas Integrated Into Paper‐based Poc...mentioning

confidence: 99%

Bottom‐up DNA nanostructure‐based paper as point‐of‐care diagnostic: From method to device

Gao,

Feng,

Deng

et al. 2024

Interdisciplinary Medicine

View full text Add to dashboard Cite

Paper‐based devices have attracted considerable attention in point‐of‐care testing (POCT) due to their simple operation and portability. The performance of paper‐based POC assays is further enhanced by coupling with functional nucleic acids (FNAs), which are able to selectively recognize and bind to targets, amplify and transduce signals. Several high‐performance paper‐based POC assays have been developed, resulting from the different spatial structures of the paper‐based device and detection strategies using different FNAs. In this review, we first introduce FNAs and paper‐based devices, including their concepts, classifications and advances. The following section focuses on the application of these FNAs in POC assays using paper‐based devices, taking into account their spatial one‐, two‐ and three‐dimensional structures. Finally, the challenges and perspectives of the application of FNAs in paper‐based POCT are discussed.

show abstract

“…Potential applications of anti-VEGF aptamers include the inhibition of angiogenesis-driven diseases of the eye such as nAMD and DR. [74,75] Anti-VEGF aptamers have recently been approved for treatment by ocular injection in cases of AMD and DR. [74,75] Thus, some researchers have already hypothesized that nanomaterials could serve as good carriers for anti-VEGF aptamers. [76,77] Shoval et al designed an anti-VEGF aptamer that was functionalized on CDs, and the hybrid nanoparticles were used for ocular nanomedicine applications as shown in Figure 6a. [78] The CDs were modified with a nucleic acid probe that complemented the anti-VEGF aptamer.…”

Section: Cds With Anti-vegf Aptamers For Treatment Of Namd and Drmentioning

confidence: 99%

Functional Carbon Quantum Dots for Ocular Imaging and Therapeutic Applications

Kumar

Sher

Rencus‐Lazar

et al. 2022

Small

View full text Add to dashboard Cite

functional groups such as CHO, CO, NH 2 , OH, COOH, COC, CN, NO, SH, or polymer aggregates. [11] Moreover, CDs are considered to be the most recent form of zero-dimensional carbon, with a diameter of less than 10 nm and excellent fluorescent properties. [12] These properties have led to their application in biomedical engineering [13] and sensor technology, [14,15] including heavy metal ion detection, [16] fluorescent labeling and nucleus targeted imaging of cells, [17] targeting of drug delivery for anti-tumor therapy, [18] photovoltaic devices/solar cell, [19] photocatalysts, [20] dye degradation, [21] lubricant additive, [22] supercapacitor, [23] nanoelectronic devices, [24] fuel cells, [25] anti-viral therapy, [26] photodynamic therapy, [27] gene delivery, [28] and disruption of the fibrillation of amyloidogenic peptides, such as Aβ. [29,30] Recently, Shah et al. have investigated the presence of Aβ in aging eyes and its significance in relation to Alzheimer's disease (AD) pathology. [31] They have also discussed clinical studies investigating the in vivo ocular imaging of Aβ and its relationship to brain Aβ burden, as well as therapies that target ocular Aβ. [31] Therefore, the characterization of retinal Aβ is also necessary in order to differentiate it from eye-related diseases.According to the World Health Organization, more than 2.2 billion individuals were affected by some form of visual impairment in 2020, with an estimated 35 million blind individuals. [32][33][34] Among the leading causes of vision loss Carbon quantum dots (CDs) are a class of emerging carbonaceous nanomaterials that have received considerable attention due to their excellent fluorescent properties, extremely small size, ability to penetrate cells and tissues, ease of synthesis, surface modification, low cytotoxicity, and superior water dispersion. In light of these properties, CDs are extensively investigated as candidates for bioimaging probes, efficient drug carriers, and disease diagnostics. Functionalized CDs represent a promising therapeutic candidate for ocular diseases. Here, this work reviews the potential use of functionalized CDs in the diagnosis and treatment of eye-related diseases, including the treatment of macular and anterior segment diseases, as well as targeting Aβ amyloids in the retina.

show abstract

Aptamer-Functionalized Hybrid Nanostructures for Sensing, Drug Delivery, Catalysis and Mechanical Applications

Cited by 27 publications

References 223 publications

Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect

Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect

Bottom‐up DNA nanostructure‐based paper as point‐of‐care diagnostic: From method to device

Functional Carbon Quantum Dots for Ocular Imaging and Therapeutic Applications

Contact Info

Product

Resources

About